Subterms
What can I do to take good care of my brain and lower my risk for a neurological disease? That’s the No. 1 question neurologist Dr. Jonathan Rosand hears from his patients (and their family members) at the Massachusetts General Hospital McCance Center for Brain Health. To help answer it, he and his colleagues, with […] More
The Japanese biochemist found in the 1970s that cholesterol-lowering drugs lowered the LDL, or “bad” cholesterol, level in the blood.Akira Endo, a Japanese biochemist whose research on fungi helped to lay the groundwork for widely prescribed drugs that lower a type of cholesterol that contributes to heart disease, died on June 5. He was 90.Chiba Kazuhiro, the president of Tokyo University of Agriculture and Technology, where Dr. Endo was a professor emeritus, confirmed the death in a statement. The statement did not give a cause or say where he died.Cholesterol, mostly made in the liver, has important functions in the body. It is also a major contributor to coronary artery disease, a leading cause of death in the United States, Japan and many other countries.In the early 1970s, Dr. Endo grew fungi in an effort to find a natural substance that could block a crucial enzyme that is part of the production of cholesterol. Some scientists worried that doing so might threaten cholesterol’s positive functions.But by 1980, Dr. Endo’s team had found that a cholesterol-lowering drug, or statin, lowered the LDL, or “bad” cholesterol level, in the blood. And by 1987, after other researchers in the field had published additional research on statins, Merck was manufacturing the first licensed statin.Such drugs have proven effective in reducing the risk for cardiovascular disease, and millions of people in the United States and beyond now take them for high levels of LDL.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More
And they’re increasingly common. Here’s what to know about the shared risk factors for these diseases.Heart disease, diabetes and kidney disease are among the most common chronic illnesses in the United States — and they’re all closely connected.Adults with diabetes are twice as likely to have heart disease or a stroke compared with those who don’t have diabetes. People with diabetes — Type 1 and Type 2 — are also at risk of developing kidney disease. And when the kidneys don’t work well, a person’s heart has to work even harder to pump blood to them, which can then lead to heart disease.The three illnesses overlap so much that last year the American Heart Association coined the term cardiovascular-kidney-metabolic syndrome to describe patients who have two or more of these diseases, or are at risk of developing them. A new study suggests that nearly 90 percent of American adults already show some early signs of these connected conditions.While only 15 percent of Americans meet the criteria for advanced stages of C.K.M. syndrome, meaning they have been diagnosed with diabetes, heart disease or kidney disease or are at high risk of developing them, the numbers are still “astronomically higher than expected” said Dr. Rahul Aggarwal, a cardiology fellow at Brigham and Women’s Hospital in Boston and co-author of the study.The research suggests that people should pay attention to shared risk factors for these diseases early on — including excess body fat, uncontrolled blood sugar, high blood pressure and high cholesterol or triglyceride levels.A Dangerous CycleYour kidneys, heart and metabolic system (which helps process the food you eat into energy and maintains your blood sugar levels) work closely together. If something goes awry with one, it can lead to problems with the others.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More
